Changeflow GovPing Pharma & Drug Safety Copper-Chelating Butanediamine Derivatives Pate...
Routine Rule Added Final

Copper-Chelating Butanediamine Derivatives Patent EP3823977A1

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published application EP3823977A1 for (pyridinylmethyl)butanediamine derivatives capable of chelating copper, filed by Cold Spring Harbor Laboratory and Depymed, Inc. The patent covers pharmaceutical compounds with applications in liver diseases, neurological conditions, and cancer treatment. Designated states include all EU member states plus EEA countries.

What changed

The European Patent Office granted patent EP3823977A1 for novel (pyridinylmethyl)butanediamine compounds with copper-chelating properties. The patent application was filed by Cold Spring Harbor Laboratory and Depymed, Inc., with inventors including Nicholas Tonks, Navasona Krishnan, and Andreas Grill. The compounds are classified under multiple therapeutic categories including liver diseases (A61P 1/16), neurological conditions (A61P 25/00), and cancer (A61P 35/00).

For pharmaceutical developers and researchers in copper metabolism disorders, this patent establishes intellectual property protection for copper-chelating butanediamine derivatives. Companies developing treatments for Wilson's disease, Alzheimer's disease, or cancer therapies targeting copper-dependent pathways should assess freedom-to-operate before commencing related R&D programs.

What to do next

  1. Monitor freedom-to-operate if developing copper chelation therapies
  2. Review patent claims for potential licensing opportunities

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

(PYRIDINYLMETHYL)BUTANEDIAMINE DERIVATIVES THAT CHELATE COPPER

Publication EP3823977A1 Kind: A1 Apr 01, 2026

Applicants

Cold Spring Harbor Laboratory, Depymed, Inc.

Inventors

TONKS, Nicholas, KRISHNAN, Navasona, GRILL, Andreas

IPC Classifications

C07J 9/00 20060101AFI20260114BHEP C07J 43/00 20060101ALI20260114BHEP C07D 401/12 20060101ALI20260114BHEP A61P 1/16 20060101ALI20260114BHEP A61P 25/00 20060101ALI20260114BHEP A61P 35/00 20060101ALI20260114BHEP C07D 213/38 20060101ALI20260114BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3823977A1

Who this affects

Applies to
Pharmaceutical companies Researchers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination Drug compound research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.